Radiopharm Theranostics Limited (ASX:RAD)
Australia · Delayed Price · Currency is AUD | Market Cap | 81.52M |
| Revenue (ttm) | 12.51M +538.9% |
| Net Income | -38.34M |
| EPS | -0.02 |
| Shares Out | 3.54B |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 635,615 |
| Average Volume | 3,162,627 |
| Open | 0.0220 |
| Previous Close | 0.0230 |
| Day's Range | 0.0220 - 0.0230 |
| 52-Week Range | 0.0170 - 0.0400 |
| Beta | 0.94 |
| RSI | 44.73 |
| Earnings Date | Feb 26, 2026 |
About Radiopharm Theranostics
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung the... [Read more]
Financial Performance
In fiscal year 2025, Radiopharm Theranostics's revenue was 12.51 million, an increase of 538.86% compared to the previous year's 1.96 million. Losses were -38.34 million, -20.04% less than in 2024.
Financial StatementsNews
RAD Increases Ownership in Radiopharm Ventures to 87.5%
SYDNEY, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, Nasdaq: RADX, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative on...
Why Is Radiopharm Theranostics Stock Rallying Over 140%?
Radiopharm Theranostics Limited (NASDAQ: RADX) stock is trading higher on Monday, with a session volume of 21.33 million compared to the average volume of 26.81 thousand, as per data from Benzinga Pro...
Radiopharm Theranostics Achieves Primary Endpoint in 92% of Patients at Interim Analysis of RAD 101 Phase 2b Imaging Trial in Brain Metastases
92% of evaluable patients at interim analysis treated with RAD 101 achieved concordance¹ with MRI imaging (the primary endpoint) with significant and selective tumor uptake in suspected or recurrent b...
Radiopharm Theranostics (RADX): Analyst Maintains 'Buy' as Price Target Adjusts | RADX Stock News
Radiopharm Theranostics (RADX): Analyst Maintains 'Buy' as Price Target Adjusts | RADX Stock News
Lantheus (LNTH) Commits to Significant Investment in Radiopharm Theranostics
Lantheus (LNTH) Commits to Significant Investment in Radiopharm Theranostics
Radiopharm Theranostics completes A$35 million Placement and launches a A$5 million Share Purchase Plan
SYDNEY, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics Limited (ASX:RAD; Nasdaq:RADX), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeu...
Regal-backed biotech Radiopharm Theranostics launches $35m placement
The $88 million market cap company had its stockbroker Bell Potter canvassing investor interest at 3¢ per share, an 18.9 per cent discount to the last close.
Radiopharm Theranostics Limited - Special Call
Radiopharm Theranostics reports Fiscal Year 2025 Financial Results and Business Update
On track to complete enrollment of first two cohorts of RAD204 following positive recommendation from DSMC to escalate dose to 60mCi of Lu177
Dr Oliver Sartor Appointed to Radiopharm Scientific Advisory Board
SYDNEY, July 22, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radioph...
Radiopharm Theranostics Reports Preclinical Lu177-B7H3-mAb Data Demonstrating Favourable Biodistribution and High Tumour Uptake
Supports plans to advance the RV01 program to first-in-human therapeutic basket study in solid tumour cancers Data completes preclinical package for Investigational New Drug submission in mid-2025 wit...
ITM and Radiopharm Sign Supply Agreement for n.c.a. Lutetium-177
GARCHING / MUNICH, Germany and SYDNEY, May 19, 2025 (GLOBE NEWSWIRE) -- ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and Radiopharm Theranostics (ASX:RAD; N...
Radiopharm Theranostics: Radiotherapeutic Biotech With PD-L1 And HER2 Targeting
This S&P Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Top Wall Street analysts initiated coverage on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page ....
Radiopharm Announces Strategic Co-Development Partnership with Lantheus for Australia
SYDNEY, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radioph...
RAD 202 Receives Approval to Start Phase 1 Therapeutic Trial
SYDNEY, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radioph...
Deutsche Bank Appointed as Depositary Bank for the Sponsored American Depositary Receipt Program of Radiopharm Theranostics Limited
NEW YORK--(BUSINESS WIRE)--Deutsche Bank announced today its appointment as depositary bank for the American Depositary Receipt program of Radiopharm Theranostics Limited. Radiopharm Theranostics Limi...